BMGL on Nasdaq

Basel Medical Group Ltd

Basel Medical Group Ltd is an offices and Clinics of Doctors of Medicine services company.² It is headquartered in Singapore, Singapore.² Its shares trade on Nasdaq under the symbol BMGL.²

Price unavailable

Last updated Oct 21, 2026.

Overview

$8.9MRevenue, fiscal 2025³

-$8.4MNet income, fiscal 2025³

Compare with Cardiff Lexington Corp, HealthLynked Corp or Concord Medical Services Holdings Ltd, or pick any stock.

TickerBMGL on Nasdaq²
IndustryServices-Offices & Clinics of Doctors of Medicine²
HeadquartersSingapore, Singapore²
Incorporated inVirgin Islands, British⁴
Business address600 North Bridge Road, #12-02/03, Parkview Square, Singapore, U0 188778⁴
Filer category, Emerging growth company⁴
Legal formcompany limited by shares²
LEI529900I1F9NKYIFYQU86²
StatusActive²
LEI statusIssued and current²
Registered addressc/o Maples Corporate Services (BVI) Limited, Kingston Chambers, PO Box 173, Road Town, VG1110 Tortola, British Virgin Islands²
Registered withRegistry of Corporate Affairs (British Virgin Islands Financial Services Commission), 2129740²

See how the biggest companies compare on our leaderboards

Group Ltd. Our Group through Bethesda Medical operates six general practice clinics in Singapore.⁵ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-94.0%Net margin³

-195.6%Return on equity³

0.54×Debt to equity³

-$3.6MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2025

Other costs

Other costs95¢$8.4M
Interest2¢$160.3K
Income tax4¢$328.2K

Out of $8.9M in revenue.³ The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2025-06-30	2024-06-30
Revenue	11.3M SGD	10.1M SGD
Other income	1.8M SGD	461.0K SGD
Consumables, medical supplies and other related expenses	-2.6M SGD	-2.2M SGD
Employee benefit expenses	-6.4M SGD	-3.6M SGD
Depreciation expense	-1.2M SGD	-528.7K SGD
Rent expense	-141.1K SGD	-3.2K SGD
Other operating expense	-3.3M SGD	-1.5M SGD
Impairment loss on goodwill	-10.3M SGD
Finance cost	-203.9K SGD	-176.2K SGD
(Loss)/Profit before tax	-11.1M SGD	2.4M SGD
Income tax expense	417.4K SGD	-331.8K SGD
(Loss)/Profit after tax	-10.6M SGD	2.1M SGD
(Loss)/Profit for the year, representing total comprehensive income for the year	-10.6M SGD	2.1M SGD
Owners of the Company	-10.6M SGD	2.1M SGD
Non-controlling interests	-501 SGD
(Loss)/Profit for the year	-10.6M SGD	2.1M SGD
Basic	-0.45 SGD	0.13 SGD
Diluted	-0.57 SGD	0.13 SGD
Basic	18.8M shares	16.2M shares
Diluted	18.8M shares	16.2M shares

Shareholders’ equity³$4.3M in 2025−23% since 2024

Cash³$2.4M in 2025+56% since 2024

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.³

Period ending	2025-06-30	2024-06-30	2023-06-30
Right-of-use-assets	4.9M SGD	23.5K SGD
Property and equipment	388.7K SGD	34.5K SGD
Deferred tax assets	47.9K SGD	77.0K SGD
Total Non-current assets	5.4M SGD	135.0K SGD
Inventories	489.1K SGD	72.0K SGD
Trade and other receivables	9.5M SGD	2.0M SGD
Cash and cash equivalents	3.0M SGD	2.0M SGD	1.2M SGD
Deferred offering costs	31.8K SGD	1.6M SGD
Current tax assets	239.4K SGD
Total Current assets	13.3M SGD	16.2M SGD
Total assets	18.7M SGD	16.3M SGD
Deferred tax liabilities	123.8K SGD
Borrowings	3.0M SGD	1.6M SGD
Total Non-current liabilities	3.1M SGD	1.6M SGD
Trade and other payables	6.6M SGD	2.6M SGD
Borrowings	2.1M SGD	2.7M SGD
Amount due to related parties	1.5M SGD	1.3M SGD
Amount due to a former director		111.5K SGD
Asset retirement obligation	15.0K SGD	15.0K SGD
Provision for income tax		443.3K SGD
Total Current liabilities	10.2M SGD	7.2M SGD
Total liabilities	13.2M SGD	8.7M SGD
NET ASSETS	5.4M SGD	7.6M SGD
Share capital	34.2M SGD	24.5M SGD
Merger reserve arising from group restructuring	-24.5M SGD	-24.5M SGD
Retained earnings	-3.9M SGD	7.6M SGD
Translation reserve	-463.8K SGD
Non-controlling interest	3.5K SGD
Total equity	5.4M SGD	7.6M SGD	5.5M SGD

Period ending	2025-06-30	2024-06-30	2023-06-30
Right-of-use-assets	4.9M SGD	23.5K SGD
Property and equipment	388.7K SGD	34.5K SGD
Deferred tax assets	47.9K SGD	77.0K SGD
Total Non-current assets	5.4M SGD	135.0K SGD
Inventories	489.1K SGD	72.0K SGD
Trade and other receivables	9.5M SGD	2.0M SGD
Cash and cash equivalents	3.0M SGD	2.0M SGD	1.2M SGD
Deferred offering costs	31.8K SGD	1.6M SGD
Current tax assets	239.4K SGD
Total Current assets	13.3M SGD	16.2M SGD
Total assets	18.7M SGD	16.3M SGD
Deferred tax liabilities	123.8K SGD
Borrowings	3.0M SGD	1.6M SGD
Total Non-current liabilities	3.1M SGD	1.6M SGD
Trade and other payables	6.6M SGD	2.6M SGD
Borrowings	2.1M SGD	2.7M SGD
Amount due to related parties	1.5M SGD	1.3M SGD
Amount due to a former director		111.5K SGD
Asset retirement obligation	15.0K SGD	15.0K SGD
Provision for income tax		443.3K SGD
Total Current liabilities	10.2M SGD	7.2M SGD
Total liabilities	13.2M SGD	8.7M SGD
NET ASSETS	5.4M SGD	7.6M SGD
Share capital	34.2M SGD	24.5M SGD
Merger reserve arising from group restructuring	-24.5M SGD	-24.5M SGD
Retained earnings	-3.9M SGD	7.6M SGD
Translation reserve	-463.8K SGD
Non-controlling interest	3.5K SGD
Total equity	5.4M SGD	7.6M SGD	5.5M SGD

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2025-06-30	2024-06-30
(Loss)/Profit before tax	-11.1M SGD	2.4M SGD
Bad debts written off	602.3K SGD
Reversal of estimated credit losses		-55.7K SGD
Provision for estimated credit losses	277.1K SGD	50.2K SGD
Depreciation of property and equipment	107.7K SGD	30.1K SGD
Amortisation of right-of-use assets	1.1M SGD	498.6K SGD
Fixed asset written off	206.3K SGD
Impairment loss on goodwill	10.3M SGD
Interest expense	203.9K SGD	176.2K SGD
Operating cash flows before changes in working capital	1.8M SGD	3.1M SGD
Inventories	-304.3K SGD	22.6K SGD
Trade and other receivables	-8.7M SGD	-415.1K SGD
Trade and other payables	4.0M SGD	387.7K SGD
Cash (used in)/ generated from operations	-3.2M SGD	3.1M SGD
Interest paid	-648.3K SGD	-176.2K SGD
Income tax paid	-203.9K SGD	-413.6K SGD
Net cash (used in)/generated from operating activities	-4.0M SGD	2.5M SGD
Acquisition of property and equipment	-556.9K SGD	-7.9K SGD
Acquisition of subsidiary	-10.3M SGD
Cash provided by/ (used in) investing activities	-10.9M SGD	-7.9K SGD
Deferred offering costs	1.6M SGD	-1.6M SGD
Decrease in amount due from a director		1.3M SGD
Increase in amount due to related parties	138.9K SGD	1.3M SGD
Decrease/(Increase) in amount due from related parties	10.6M SGD	-73 SGD
Proceeds from borrowings	4.0M SGD
Payment of principal portion of lease liabilities	-1.3M SGD	-566.0K SGD
Write off of Right-of-use assets	183.2K SGD
Repayment of borrowings	-8.3M SGD	-2.4M SGD
(Decrease)/Increase in amount due to former director	-111.5K SGD	111.5K SGD
Non-controlling interest contributions	3.5K SGD
Share issuance	9.8M SGD
Net cash generated from/(used in) financing activities	16.5M SGD	-1.8M SGD
Net increase/(decrease) in cash and cash equivalents	1.6M SGD	733.6K SGD
Effects of currency translation on cash and cash equivalents	-463.8K SGD

Compare Basel Medical Group Ltd with another company

Corporate structure

Basel Medical Group Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Basel Medical Group Ltd

Rainforest Capital VCC Filed SCHEDULE 13G on Basel Medical Group Ltd, latest Apr 30, 2025

Basel Medical Group Ltd Singapore, Singapore

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Basel Medical Group Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$305.6K³ Jun 30, 2025
Operating-lease assets (leased space)	$3.9M³ Jun 30, 2025

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$2.4M³ Jun 30, 2025	$1.5M³ Jun 30, 2024	+56.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	10.3M SGD³ Jun 30, 2025

Inventory

Item	Latest	A year before	Change
Inventory, total	$384.5K³ Jun 30, 2025

Leadership

Who has led Basel Medical Group Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

Darren Yen Feng Chhoa2026–now

Chief financial officer

Alton Chun How Neo2026–now

Chief executive officerDarren Yen Feng Chhoa Apr 14, 2026 to now⁶
Chief financial officerAlton Chun How Neo Jul 22, 2026 to now⁷

Board members and other officers (5)

Chief Commercial OfficerBoon Chye Tan Apr 14, 2026 to now⁸
Board memberPaul D. Freudenthaler Mar 4, 2026 to now⁹
Board memberBoon Chye Tan Apr 14, 2026 to now⁸
Board memberKeng Leong Fung Apr 14, 2026 to now¹⁰
Board memberKwek Yoon Soong Apr 21, 2026 to now¹¹

Timeline

Apr 14, 2026New chief executive Darren Yen Feng Chhoa becomes CEO⁶
Aug 10, 2023Founded Basel Medical Group Ltd is founded²

Filings

81 filings to the SEC since October 2021: 2 annual reports, 9 insider forms, 1 large holders, 69 other. The latest 20:

Oct 13, 20266-K EDGAR
Oct 9, 20266-K EDGAR
Oct 8, 2026424B4 EDGAR
Oct 1, 20263 EDGAR
Sep 29, 2026EFFECT EDGAR
Sep 23, 2026F-1/A EDGAR
Sep 17, 2026F-1 EDGAR
Sep 2, 20266-K EDGAR
Aug 10, 20266-K EDGAR
Jul 31, 2026DRS EDGAR
Jul 22, 20263 EDGAR
Jul 10, 20266-K EDGAR
Jun 26, 20266-K EDGAR
Jun 10, 20266-K EDGAR
Jun 5, 20266-K EDGAR
Apr 21, 20263 EDGAR
Apr 15, 20263 EDGAR
Apr 14, 20263 EDGAR
Apr 14, 20263 EDGAR
Apr 14, 20263 EDGAR

The 81 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Rainforest Capital VCCSCHEDULE 13G, 1 filing Apr 30, 2025¹²

SEC filer profile

How Basel Medical Group Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARBasel Medical Group Ltd¹
CIK0002004489
Filer statusNon-accelerated filer an emerging growth company; a shell company⁵
Incorporated inD8⁵
Fiscal year endsJune 30¹
Industry code (SIC)8011 Services-Offices & Clinics of Doctors of Medicine¹
SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
Business address600 North Bridge Road, #12-02/03, Parkview Square, Singapore, U0 188778¹
Phone65 6291 9188¹
Shares outstanding18,785,750 shares as of Jun 30, 2025⁵
AuditorNLA DFK Assurance PAC, Singapore PCAOB ID 6889; no auditor attestation of internal control over financial reporting⁵
On EDGAR sinceFeb 9, 2024¹
Filings81 in all: 6-K (31), 3 (9), CORRESP (6), DRSLTR (5), F-1/A (5), UPLOAD (5), DRS/A (4), 424B4 (3)¹
All 18 form types
DRS (2), EFFECT (2), F-1 (2), 20-F (1), 20-F/A (1), 8-A12B (1), CERT (1), FWP (1), NT 20-F (1), SCHEDULE 13G (1)
Latest filingsAnnual report (20-F) Nov 18, 2025

Securities registered for trading

Class	Symbol	Exchange
Ordinary shares with no par value	BMGL	Nasdaq

From the cover page of the 20-F filed Nov 18, 2025 (Section 12(b) of the Exchange Act).⁵

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARBasel Medical Group Ltd filings on SEC EDGAR
2
GLEIFBasel Medical Group Ltd LEI record (529900I1F9NKYIFYQU86)
3
SEC EDGARBasel Medical Group Ltd 10-K for fiscal 2025
4
SEC EDGARBasel Medical Group Ltd filings on SEC EDGAR
5
SEC EDGARBasel Medical Group Ltd annual report, Item 1 (Business)
6
SEC EDGARDarren Yen Feng Chhoa, Chief executive officer
7
SEC EDGARAlton Chun How Neo, Chief financial officer
8
SEC EDGARBoon Chye Tan, Chief Commercial Officer
9
SEC EDGARPaul D. Freudenthaler, Board member
10
SEC EDGARKeng Leong Fung, Board member
11
SEC EDGARKwek Yoon Soong, Board member
12
SEC EDGARRainforest Capital VCC SCHEDULE 13G on Basel Medical Group Ltd